It is estimated that around 30% of women diagnosed with breast cancer each year in the UK undergo a mastectomy, with 21% of these patients opting to have immediate breast reconstruction. FixNip NRI: The Nipple and Areola Reconstruction Implant is a medical device that provides the answer to breast reconstruction for thousands of women around the world. It is a biocompatible smooth silicone implant specially designed for a long-lasting reconstruction of the Nipple-Areola Complex. The product has

BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a $30 million Series A financing, bringing the total raised so far to $54M, including the seed financing in 2021. The financing was led by Lapam Capital with strong support from existing investors CDH Investments, 5Y Capital, and Yael Capital, as well as new partici

REDMOND, Wash., July 26, 2024 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS), in its 2025 Physician Fee Schedule (PFS) Proposed Rule, announced its intent to create three new supply codes in its direct Practice Expense (PE) Database to describe the inFlow Voiding Prosthesis and facilitate appropriate payment rates for related physician services. Vesiflo appreciates CMS' acknowledgment of inconsistencies in pricing for the relevant physician service codes by the Medicare Admin

Researchers demonstrate the intricate interactions between single-stranded DNA sequences and carbon nanotubes BUSAN, South Korea, July 26, 2024 /PRNewswire/ -- Single-walled carbon nanotubes (SWCNTs) have emerged as promising candidates for applications in biotechnology and nanoelectronics due to their exceptional physical and chemical properties. Despite their potential, challenges like insolubility and toxicity have hindered their widespread use. Prior studies have been investigating diverse

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer’s disease patients CAMBRIDGE, Massachusetts and TORONTO, Ontario, July 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody ther

Ian Davis Will Use His Grant to Build an Affordable, User-Assembled Prosthetic Hand Device GREENWICH, Conn., July 26, 2024 /PRNewswire/ -- O'Shaughnessy Ventures LLC (OSV), an investment firm that empowers creators, has awarded an O'Shaughnessy Fellowship to Ian Davis, a product design engineer based in Oregon. Davis will continue to design, develop and bring to market an affordable prosthetic hand, incorporating his engineering expertise and real-world experience as an amputee, to improve upon

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 2024年7月23日，据CDE官网显示，广州泛恩生物科技有限公司（以下简称“泛恩生物”或“公司”）申请的“TAL-T细胞注射液”已获得临床试验默示许可，适应症为晚期恶性实体瘤（受理号CXSL2400285）。 截图来源：CDE 此次获批IND的细胞注射液是全球首款TAL-T细胞疗法，由泛恩生物采用自主研发的核心技术，从肿瘤相关淋巴结中制备的高质量自体抗肿瘤T细胞。 截图来源：药融云全球药物研发数据库 该疗法成功解决了TIL等自体抗肿瘤T细胞疗法所面临的制备成功率低、只适合小部分患者的难题，将自体抗肿瘤T细胞疗法成功应用到大部分实体肿瘤患者。TAL-T细胞疗法具有适应症广、无遗传修饰、制备周期短、治疗效果佳等优势。目前正在开展IIT临床研究，显示出了优良的安全性和显著的有效性。 截图来源：药融云全球药物研发数据库 肿瘤相关淋巴结T细胞（TAL-T：Tumor Associated Lymphnode T cell）疗法，是指将肿瘤相关

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 7月25日，据CDE官网显示，兴齐眼药公司申报的1类新药SQ-22031滴眼液获得多项临床试验默示许可，拟用于治疗神经营养性角膜炎、干眼。根据企业公告介绍，这是其开发的一款治疗用生物制品1类新药。 截图来源：CDE 干眼症为常见慢性眼疾，因泪膜不足致干涩、疼痛、不适，重则损害视力。据统计，2022年我国干眼患者约有3亿人，发病率高达21%~30%。神经营养性角膜炎是由角膜感觉神经损伤引起的角膜退行性病变，已被列入我国第二批罕见病目录。研究显示，引起角膜知觉减退的原因较多样，从三叉神经核到角膜神经末梢，所有影响感觉神经的疾病均有可能导致角膜知觉减退。 SQ-22031滴眼液是兴齐眼药开发的一款治疗用生物制品，其临床试验申请于今年4月获得CDE受理。本次获批临床，意味着其即将针对这两类疾病开展临床研究。兴齐眼药表示，已经完成SQ-22031滴眼液药学及非临床药理毒理学等多方面的研究，研究结果表明该产品具有良好的安全性及临床开发价值。本次

来源：药融云新药笔记，更多新药内容点击上方名片☝︎关注药融云新药笔记。 1.吉利德长效HIV疗法lenacapavir登《新英格兰医学杂志》，每半年注射一次，100%有效！ 7月25日，吉利德科学（Gilead Sciences）公布其关键3期PURPOSE 1试验的中期分析详细结果。该公司每半年注射一次的艾滋病毒（HIV）衣壳抑制剂lenacapavir在女性中的HIV预防用途上显示出100%的有效性，相比于每日一次口服疗法以及HIV的背景发病率皆表现出显著的优效性。据此积极结果，独立数据监测委员会建议吉利德提早解盲，并提供所有受试者开放标签的lenacapavir。该试验的详细结果也同步刊登于《新英格兰医学杂志》（NEJM）当中。PURPOSE 1 是一项 3 期、双盲、随机的非劣性研究，旨在评估每半年一次皮下注射 Lenacapavir 进行暴露前预防 (PrEP) 和每日一次口服 Truvada（舒发泰®，emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF） 或 Descovy（达可挥®，emtr

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 7月18日，据国家药监局发布公告，对韩国大熊制药（DAEWOONG BIO INC.）的注射用头孢地嗪钠开展境外生产现场动态检查。因大熊制药未按要求接受国家药监局对于国家组织集采中选药品该药品的境外现场动态检查，国家药监局将该检查判定为“不符合要求”，并对该产品采取暂停进口、销售和使用措施。 18亿+集采进口药遭停售，市场销售额逐年下降！ 注射用头孢地嗪钠是一种抗生素类药物，属于第三代头孢菌素类。用于敏感细菌引起的感染，如上、下泌尿道感染,下呼吸道感染，淋病等。据药融云数据库显示，这款昔日在全国院内市场销售额超18亿元的大品种，近年来销售额显著下滑，已缩减至仅3亿元左右的规模。近三年来，注射用头孢地嗪钠在全国医院内的市场规模持续萎缩，呈现出明显的下降趋势。2022年销售额达6.93亿元，同比下滑34.03%；2023年销售额达3.24亿元，同比下滑53.39%；2024年一季度表现仍不佳，销售额仅达4千万元，同比下滑59.35%。